KRAS and cancer: The current consensus framework (the consensus molecular subtypes, CMS) defines four biologically distinct subgroups with associations to clinicopathological factors (cancer stage and tumor localization), molecular markers (microsatellite instability [MSI] and KRAS/BRAFV600E mutations), and patient survival [3].